Knight Therapeutics Inc. (GUD.TO)

CAD 5.77

(3.22%)

Long Term Debt Summary of Knight Therapeutics Inc.

Knight Therapeutics Inc.'s latest annual long term debt in 2023 was 44.01 Million CAD , down -23.38% from previous year.
Knight Therapeutics Inc.'s latest quarterly long term debt in 2024 Q1 was 42.92 Million CAD , down -2.48% from previous quarter.
Knight Therapeutics Inc. reported annual long term debt of 57.44 Million CAD in 2022, up 352.99% from previous year.
Knight Therapeutics Inc. reported annual long term debt of 12.68 Million CAD in 2021, up 398.7% from previous year.
Knight Therapeutics Inc. reported quarterly long term debt of 33.96 Million CAD for 2024 Q2, down -20.88% from previous quarter.
Knight Therapeutics Inc. reported quarterly long term debt of 44.01 Million CAD for 2023 Q4, down -19.23% from previous quarter.

Annual Long Term Debt Chart of Knight Therapeutics Inc. (2023 - 2013)

Historical Annual Long Term Debt of Knight Therapeutics Inc. (2023 - 2013)

Year	Long Term Debt	Long Term Debt Growth
2023	44.01 Million CAD	-23.38%
2022	57.44 Million CAD	352.99%
2021	12.68 Million CAD	398.7%
2020	2.54 Million CAD	-74.14%
2019	9.83 Million CAD	0.0%
2018	- CAD	0.0%
2017	- CAD	0.0%
2016	- CAD	0.0%
2015	- CAD	0.0%
2014	- CAD	0.0%
2013	- CAD	0.0%

Year	Long Term Debt	Long Term Debt Growth
2024 Q1	42.92 Million CAD	-2.48%
2024 Q2	33.96 Million CAD	-20.88%
2023 Q4	44.01 Million CAD	-19.23%
2023 Q2	56.16 Million CAD	-6.73%
2023 Q1	60.21 Million CAD	4.81%
2023 Q3	54.49 Million CAD	-2.97%
2023 FY	44.01 Million CAD	-23.38%
2022 Q3	11.62 Million CAD	-2.02%
2022 Q2	11.86 Million CAD	-15.1%
2022 FY	57.44 Million CAD	352.99%
2022 Q1	13.97 Million CAD	10.16%
2022 Q4	57.44 Million CAD	394.3%
2021 Q1	2.17 Million CAD	-14.51%
2021 Q4	12.68 Million CAD	366.59%
2021 Q3	2.71 Million CAD	-6.08%
2021 Q2	2.89 Million CAD	33.12%
2021 FY	12.68 Million CAD	398.7%
2020 Q3	5.19 Million CAD	-9.03%
2020 Q4	2.54 Million CAD	-51.01%
2020 FY	2.54 Million CAD	-74.14%
2020 Q2	5.7 Million CAD	-34.36%
2020 Q1	8.69 Million CAD	-11.6%
2019 FY	9.83 Million CAD	0.0%
2019 Q4	9.83 Million CAD	1298.86%
2019 Q3	703 Thousand CAD	-3.83%
2019 Q2	731 Thousand CAD	-7.93%
2019 Q1	794 Thousand CAD	0.0%
2018 Q4	- CAD	0.0%
2018 Q2	- CAD	0.0%
2018 Q1	- CAD	0.0%
2018 FY	- CAD	0.0%
2018 Q3	- CAD	0.0%
2017 Q2	- CAD	0.0%
2017 Q4	- CAD	0.0%
2017 FY	- CAD	0.0%
2017 Q1	- CAD	0.0%
2017 Q3	- CAD	0.0%
2016 Q2	- CAD	0.0%
2016 Q3	- CAD	0.0%
2016 Q4	- CAD	0.0%
2016 FY	- CAD	0.0%
2016 Q1	- CAD	0.0%
2015 Q3	- CAD	0.0%
2015 FY	- CAD	0.0%
2015 Q4	- CAD	0.0%
2015 Q2	- CAD	0.0%
2015 Q1	- CAD	0.0%
2014 Q4	- CAD	0.0%
2014 Q2	- CAD	0.0%
2014 Q3	- CAD	0.0%
2014 Q1	- CAD	0.0%
2014 FY	- CAD	0.0%
2013 Q3	- CAD	0.0%
2013 FY	- CAD	0.0%

Peer Long Term Debt Comparison of Knight Therapeutics Inc.

Name	Long Term Debt	Long Term Debt Difference
Aurora Cannabis Inc.	47.57 Million CAD	7.479%
Avicanna Inc.	95.36 Thousand CAD	-46056.75%
Avant Brands Inc.	1.74 Million CAD	-2428.202%
Cardiol Therapeutics Inc.	158.53 Thousand CAD	-27664.742%
Crescita Therapeutics Inc.	815 Thousand CAD	-5300.736%
MediPharm Labs Corp.	69 Thousand CAD	-63691.304%
OrganiGram Holdings Inc.	79 Thousand CAD	-55616.456%
Canopy Growth Corporation	493.29 Million CAD	91.077%
Willow Biosciences Inc.	594 Thousand CAD	-7310.101%
Auxly Cannabis Group Inc.	81.38 Million CAD	45.915%